Untangling the Web of Antiretroviral Price Reductions. 16th Edition, July 2013
(2013; 100 pages)

Abstract

With nearly 10 million people now receiving treatment for HIV – and another 26 million eligible to receive it – the price of antiretroviral (ARV) drugs to put people on treatment remains a critical one.The 16th edition of Untangling the Web finds that although the price of first- and second-line ARVs have come down thanks to increased generic competition, third-line or salvage regimens remain exorbitantly priced, with middle-income countries such as Armenia paying more than US$13,000 per person per year for raltegravir, just one of the three or four drugs needed in a third-line cocktail.Patents remain a barrier on newer drugs and in middle-income countries, and will need to be overcome to ensure future access to them.

 
The WHO Essential Medicines and Health Products Information Portal was designed and is maintained by Human Info NGO. Last updated: August 29, 2014